Overview

Treatment of Age-Related Macular Degeneration With Anecortave Acetate

Status:
Completed
Trial end date:
2007-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to provide compassionate use of anecortave acetate sterile suspension of 15 mg for a series of five patients as a means to control classic neovascularization following failure of treatment with photodynamic therapy using Visudyne.
Phase:
Phase 2
Details
Lead Sponsor:
Manhattan Eye, Ear & Throat Hospital
Collaborator:
Alcon Research
Treatments:
Anecortave